MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (Q48342416)
Jump to navigation
Jump to search
scientific article published on 5 February 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial |
scientific article published on 5 February 2015 |
Statements
1 reference
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (English)
1 reference
1 reference
Peter Hau
1 reference
Michael Weller
1 reference
Wolfgang Wick
1 reference
Guido Reifenberger
1 reference
Jörg Felsberg
1 reference
Ghazaleh Tabatabai
1 reference
Jürgen Meixensberger
1 reference
Michael C Sabel
1 reference
Guido Nikkhah
1 reference
Joachim P Steinbach
1 reference
Ralf Ketter
1 reference
Roger Stupp
1 reference
Ulrich Herrlinger
1 reference
Antje Wick
1 reference
Oliver Bähr
1 reference
Christine Marosi
1 reference
Hans-Georg Wirsching
1 reference
Jörg C Tonn
1 reference
Peter Vajkoczy
1 reference
Bärbel Kästner
1 reference
Oliver Schnell
1 reference
Uwe Schlegel
1 reference
Roland Goldbrunner
1 reference
Krisztian Homicsko
1 reference
Josef Pichler
1 reference
Spyros Kollias
1 reference
Johannes Hüsing
1 reference
DIRECTOR Study Group
1 reference
5 February 2015
1 reference
21
1 reference
9
1 reference
2057-2064
1 reference
Identifiers
1 reference